10,11-Seco-LSD
Pharmaceutical compound
From Wikipedia, the free encyclopedia
10,11-Seco-LSD is a partial lysergamide and cyclized tryptamine related to lysergic acid diethylamide (LSD).[1] It is the seco analogue of LSD in which the bond between the 10 and 11 positions of the ergoline ring system has been broken.[1] 10,11-Seco-LSD was described in a patent by David E. Olson and colleagues at Delix Therapeutics in 2021.[1] Its pharmacology was not described.[1]

Other names"[0124]"; 9,10-Didehydro-N,N-diethyl-6-methyl-10,11-secoergoline-8β-carboxamide
ATC code
- None
| Clinical data | |
|---|---|
| Other names | "[0124]"; 9,10-Didehydro-N,N-diethyl-6-methyl-10,11-secoergoline-8β-carboxamide |
| Drug class | Partial ergoline |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| Chemical and physical data | |
| 3D model (JSmol) | |
| |
| |
See also
- Partial lysergamide
- Seco-LSD
- Secoergoline
- NDTDI (8,10-seco-LSD)
- DEIMDHPCA (3,5-seco-LSD)